175 related articles for article (PubMed ID: 35306340)
1. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA.
Liu W; Li Y; Tang Y; Song Q; Wang J; Li N; Chen S; Shi J; Wang S; Li Y; Jiao Y; Zeng Y; Jin J
EBioMedicine; 2022 Apr; 78():103945. PubMed ID: 35306340
[TBL] [Abstract][Full Text] [Related]
2. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
[TBL] [Abstract][Full Text] [Related]
4. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.
Schou JV; Larsen FO; Sørensen BS; Abrantes R; Boysen AK; Johansen JS; Jensen BV; Nielsen DL; Spindler KL
Ann Oncol; 2018 Mar; 29(3):610-615. PubMed ID: 29253083
[TBL] [Abstract][Full Text] [Related]
6. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
[TBL] [Abstract][Full Text] [Related]
7. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P
Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226
[TBL] [Abstract][Full Text] [Related]
8. A Review of Circulating Tumor DNA as a Biomarker Guide for Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer.
Yahya J; Baber M; Nabavizadeh N; Goodyear SM; Kardosh A
J Gastrointest Cancer; 2023 Dec; 54(4):1140-1150. PubMed ID: 36719559
[TBL] [Abstract][Full Text] [Related]
9. A universal cell-free DNA approach for response prediction to preoperative chemoradiation in rectal cancer.
Grinshpun A; Kustanovich A; Neiman D; Lehmann-Werman R; Zick A; Meir K; Vainer E; Granit RZ; Arad A; Daskal N; Schwartz R; Sapir E; Maoz M; Tahover E; Moss J; Ben-Dov IZ; Peretz T; Hubert A; Shemer R; Dor Y
Int J Cancer; 2023 Apr; 152(7):1444-1451. PubMed ID: 36468189
[TBL] [Abstract][Full Text] [Related]
10. Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study).
Hashimoto T; Tsukada Y; Ito M; Kanato K; Mizusawa J; Fukuda H; Tsukamoto S; Takashima A; Kanemitsu Y
BMJ Open; 2023 Aug; 13(8):e073217. PubMed ID: 37586869
[TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial.
Vidal J; Casadevall D; Bellosillo B; Pericay C; Garcia-Carbonero R; Losa F; Layos L; Alonso V; Capdevila J; Gallego J; Vera R; Salud A; Martin-Richard M; Nogué M; Cillán E; Maurel J; Faull I; Raymond V; Fernández-Martos C; Montagut C
Clin Cancer Res; 2021 May; 27(10):2890-2898. PubMed ID: 33727257
[TBL] [Abstract][Full Text] [Related]
12. Assessing circulating tumour DNA (ctDNA) as a prognostic biomarker in locally advanced rectal cancer: a systematic review and meta-analysis.
O'Sullivan NJ; Temperley HC; Kyle ET; Sweeney KJ; O'Neill M; Gilham C; O'Sullivan J; O'Kane G; Mehigan B; O'Toole S; Larkin J; Gallagher D; McCormick P; Kelly ME
Int J Colorectal Dis; 2024 May; 39(1):82. PubMed ID: 38809315
[TBL] [Abstract][Full Text] [Related]
13. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.
Murahashi S; Akiyoshi T; Sano T; Fukunaga Y; Noda T; Ueno M; Zembutsu H
Br J Cancer; 2020 Sep; 123(5):803-810. PubMed ID: 32565539
[TBL] [Abstract][Full Text] [Related]
14. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer.
Hofste LSM; Geerlings MJ; von Rhein D; Rütten H; Westenberg AH; Weiss MM; Gilissen C; Hofste T; van der Post RS; Klarenbeek BR; de Wilt JHW; Ligtenberg MJL;
Eur J Surg Oncol; 2023 Jul; 49(7):1283-1290. PubMed ID: 36740555
[TBL] [Abstract][Full Text] [Related]
16. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.
Wang S; Xia Z; You J; Gu X; Meng F; Chen P; Tang W; Bao H; Zhang J; Wu X; Shao Y; Wang J; Zuo X; Xu L; Yin R
Cancer Res Commun; 2023 May; 3(5):933-942. PubMed ID: 37377889
[TBL] [Abstract][Full Text] [Related]
18. Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.
Vessies DCL; Schuurbiers MMF; van der Noort V; Schouten I; Linders TC; Lanfermeijer M; Ramkisoensing KL; Hartemink KJ; Monkhorst K; van den Heuvel MM; van den Broek D
Mol Oncol; 2022 Jul; 16(14):2719-2732. PubMed ID: 35674097
[TBL] [Abstract][Full Text] [Related]
19. The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
Van Paemel R; Vandeputte C; Raman L; Van Thorre J; Willems L; Van Dorpe J; Van Der Linden M; De Wilde J; De Koker A; Menten B; Devalck C; Vicha A; Grega M; Schleiermacher G; Iddir Y; Chicard M; van Zogchel L; Stutterheim J; Lak NSM; Tytgat GAM; Laureys G; Speleman F; De Wilde B; Lammens T; De Preter K; Van Roy N
Eur J Cancer; 2022 Jan; 160():12-23. PubMed ID: 34794856
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA to Predict Radiographic and Pathologic Response to Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
Alden SL; Lee V; Narang AK; Meyer J; Gearhart SL; Christenson ES
Oncologist; 2024 Mar; 29(3):e414-e418. PubMed ID: 38180954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
